{"id":"W3164778783","doi":"10.1136/annrheumdis-2021-eular.172","title":"POS0436 PATIENT CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB: THE OM1 RA REGISTRY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Genentech; Celgene; Gilead Sciences; Momenta Pharmaceuticals; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Medical prescription; Randomized controlled trial; Clinical trial; Pharmacy; Disease; Physical therapy; Family medicine; Pharmacology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006350333,0.0003526154,0.0008106761,0.001187844,0.0003253595,0.0008883351,0.0004668084,0.0005772108,0.003031258],"category_scores_gemma":[0.002059861,0.0002756055,0.0007399621,0.004129767,0.000195582,0.0008512175,0.0005517019,0.0007575611,0.0008524071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004249083,"about_ca_system_score_gemma":0.0005522573,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003136137,"about_ca_topic_score_gemma":0.004546226,"domain_scores_codex":[0.9991973,0.0001367398,0.0001503035,0.0002145264,0.0001372789,0.000163837],"domain_scores_gemma":[0.998262,0.0002253943,0.001000021,0.0001584909,0.0001525897,0.0002015746],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001825602,0.00009552974,0.987242,0.0000909338,0.0004247797,0.0001471184,0.00004300868,0.0002233907,0.0002841899,0.0001600059,0.004724328,0.004739161],"study_design_scores_gemma":[0.0001626824,0.0001863284,0.9957962,0.00004158735,0.0001973704,0.0003749153,0.0001059684,0.0002499547,0.00009226891,0.000123488,0.002650493,0.00001879221],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9560621,0.001816232,0.0001725916,0.0002601032,0.00005783179,0.0000338747,0.03777387,0.00002757899,0.003795955],"genre_scores_gemma":[0.9686284,0.0008303522,0.0001738944,0.0002330514,0.00009951018,0.00008193638,0.02896582,0.00001727441,0.000969564],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003136137,"threshold_uncertainty_score":0.01014054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01192154788568837,"score_gpt":0.2490451790269996,"score_spread":0.2371236311413112,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}